ProfileGDS5678 / 1455538_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 84% 84% 82% 84% 85% 86% 84% 84% 84% 85% 84% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2558985
GSM967853U87-EV human glioblastoma xenograft - Control 26.4078985
GSM967854U87-EV human glioblastoma xenograft - Control 36.2635284
GSM967855U87-EV human glioblastoma xenograft - Control 46.4383884
GSM967856U87-EV human glioblastoma xenograft - Control 56.0474182
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0437784
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2725285
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4296286
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2508984
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2599984
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2526984
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4577485
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1799984
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1718484